Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.046
Sell
RSI(14)
40.159
Neutral
STOCH(KDJ)(9,3,3)
25.673
Neutral
ATR(14)
0.188
Low Volatility
CCI(14)
-109.824
Sell
Williams %R
69.637
Sell
TRIX(12,20)
-0.418
Sell
StochRSI(14)
63.540
Buy
BioLine RX Ltd
BLRX3.040USD
+0.080+2.70%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
13.23MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of BioLine RX Ltd
Currency: USD Updated: 2025-12-19Key Insights
BioLine RX Ltd's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 183/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 26.00.In the medium term, the stock price is expected to trend down.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioLine RX Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
26.000
Target Price
+683.13%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
BioLine RX Ltd Highlights
StrengthsRisks
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Growing
The company is in a growing phase, with the latest annual income totaling USD 28.94M.
Overvalued
The company’s latest PE is -2.10, at a high 3-year percentile range.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of BioLine RX Ltd is 5.90, ranking 324/404 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 427.00K, representing a year-over-year decrease of 91.36%, while its net profit experienced a year-over-year decrease of 83.22%.
Score
Financials
5.62
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.78
Operational Efficiency
2.83
Growth Potential
5.17
Shareholder Returns
7.07
BioLine RX Ltd's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of BioLine RX Ltd is 7.46, ranking 124/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.10, which is -63.59% below the recent high of -0.77 and -96588.23% above the recent low of -2032.77.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 183/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19The current earnings forecast score of BioLine RX Ltd is 8.00, ranking 168/404 in the Biotechnology & Medical Research industry. The average price target for BioLine RX Ltd is 26.00, with a high of 40.00 and a low of 12.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
26.000
Target Price
+683.13%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
BioLine RX Ltd
BLRX
2
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of BioLine RX Ltd is 4.42, ranking 361/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.65 and the support level at 2.65, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.033
Buy
MA10
3.159
Sell
MA20
3.260
Sell
MA50
3.436
Sell
MA100
3.633
Sell
MA200
3.707
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-19Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of BioLine RX Ltd is 2.74, ranking 213/404 in the Biotechnology & Medical Research industry. The company's beta value is 1.28. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.28
VaR
+7.18%
240-Day Maximum Drawdown
+62.48%
240-Day Volatility
+117.12%
Return
Best Daily Return
60 days
+7.69%
120 days
+16.16%
5 years
+52.98%
Worst Daily Return
60 days
-6.92%
120 days
-7.18%
5 years
-40.87%
Sharpe Ratio
60 days
-1.41
120 days
-1.14
5 years
-0.43
Risk Assessment
Maximum Drawdown
240 days
+62.48%
3 years
+97.52%
5 years
+98.76%
Return-to-Drawdown Ratio
240 days
-0.85
3 years
-0.30
5 years
-0.20
Skewness
240 days
-0.17
3 years
-0.28
5 years
+0.35
Volatility
Realised Volatility
240 days
+117.12%
5 years
+103.63%
Standardised True Range
240 days
+11.07%
5 years
+116.65%
Downside Risk-Adjusted Return
120 days
-238.78%
240 days
-238.78%
Maximum Daily Upside Volatility
60 days
+44.46%
Maximum Daily Downside Volatility
60 days
+38.55%
Liquidity
Average Turnover Rate
60 days
+0.01%
120 days
+0.03%
5 years
--
Turnover Deviation
20 days
-97.33%
60 days
-93.56%
120 days
-68.42%
Peer Comparison
Biotechnology & Medical Research
BioLine RX Ltd
BLRX
5.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of BioLine RX Ltd?
The TradingKey Stock Score provides a comprehensive assessment of BioLine RX Ltd based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of BioLine RX Ltd’s performance and outlook.
How do we generate the financial health score of BioLine RX Ltd?
To generate the financial health score of BioLine RX Ltd, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects BioLine RX Ltd's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of BioLine RX Ltd.
How do we generate the company valuation score of BioLine RX Ltd?
To generate the company valuation score of BioLine RX Ltd, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare BioLine RX Ltd’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of BioLine RX Ltd’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of BioLine RX Ltd.
How do we generate the earnings forecast score of BioLine RX Ltd?
To calculate the earnings forecast score of BioLine RX Ltd, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on BioLine RX Ltd’s future.
How do we generate the price momentum score of BioLine RX Ltd?
When generating the price momentum score for BioLine RX Ltd, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of BioLine RX Ltd’s prices. A higher score indicates a more stable short-term price trend for BioLine RX Ltd.
How do we generate the institutional confidence score of BioLine RX Ltd?
To generate the institutional confidence score of BioLine RX Ltd, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about BioLine RX Ltd’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of BioLine RX Ltd.
How do we generate the risk management score of BioLine RX Ltd?
To assess the risk management score of BioLine RX Ltd, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of BioLine RX Ltd’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of BioLine RX Ltd.
